- Report
- April 2025
- 898 Pages
Global
From €5339EUR$5,850USD£4,552GBP
- Report
- May 2024
- 128 Pages
Global
From €5931EUR$6,499USD£5,057GBP
- Report
- May 2024
- 134 Pages
Global
From €5931EUR$6,499USD£5,057GBP
- Report
- May 2024
- 134 Pages
Global
From €5931EUR$6,499USD£5,057GBP
- Report
- January 2025
- 160 Pages
Global
From €7255EUR$7,950USD£6,186GBP
- Clinical Trials
- June 2024
- 60 Pages
Global
From €1369EUR$1,500USD£1,167GBP
- Report
- October 2023
- 159 Pages
Global
From €2145EUR$2,350USD£1,829GBP
- Report
- July 2021
- 50 Pages
China
From €2373EUR$2,600USD£2,023GBP
- Report
- August 2022
- 117 Pages
Global
From €4107EUR$4,500USD£3,502GBP
- Report
- January 2024
- 200 Pages
Global
From €3787EUR$4,150USD£3,229GBP
- Drug Pipelines
- February 2023
- 127 Pages
Global
From €13685EUR$14,995USD£11,669GBP
- Report
- December 2023
- 182 Pages
Global
€4559EUR$4,995USD£3,887GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €456EUR$500USD£389GBP

Lyrica (pregabalin) is a central nervous system (CNS) drug used to treat neuropathic pain, fibromyalgia, and generalized anxiety disorder. It is an anticonvulsant and anxiolytic drug that works by binding to certain calcium channels in the brain, reducing the release of neurotransmitters that cause pain and anxiety. Lyrica is also used to treat partial onset seizures in adults with epilepsy. It is available in both immediate-release and extended-release formulations.
Lyrica is marketed by Pfizer, Inc. in the United States and by various generic manufacturers in other countries. It is available in capsule, tablet, and oral solution forms. Lyrica is also available in combination with other drugs, such as gabapentin and duloxetine.
Other companies in the Lyrica market include Mylan, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more